Melih Tutuncu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Melih Tutuncu has a total of 213 co-authors. Here are the top co-authors by number of shared publications:
- Aksel Siva
Cerrahpasa School of Medicine, Istanbul University, Turkey
9 shared publications - Ugur Uygunoglu
Department of Neurology, School of Medicine, Istanbul University Cerrahpaşa, Istanbul 34320, Türkiye
6 shared publications - Sabahattin Saip
Neurology Istanbul University Cerrahpasa School of Medicine Istanbul Turkey
5 shared publications Aksel Siva
Department of Neurology Cerrahpasa Medical Faculty, Istanbul University‐Cerrahpasa Istanbul Turkiye
3 shared publications- Haluk Gumus
Department of Neurology, Selçuk University Faculty of Medicine, Konya, Turkey
3 shared publications Sabahattin Saip
Department of Neurology Cerrahpasa Medical Faculty, Istanbul University‐Cerrahpasa Istanbul Turkiye
3 shared publications
Latest Publications
- Open Access
- 9 April 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (11) , 2206-2216
Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering
Background: Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap. Some patients remain double‐seronegative, showing atypical features that challenge current classifications. Objective: To better characterize the phenotypic spectrum of antibody‐negative atypical inflammatory demyelinating disorders (AIDD) using unsupervised clustering. Methods: We retrospectively analyzed 316 patients (MS = 164, AQP4 + NMOSD = 36, double‐seronegative NMOSD = 21, MOGAD = 15, AIDD = 80) followed between 2010 and 2023. Principal component analysis and k‐means clustering were applied to AIDD cases using clinical, demographic, and radiological data. Results: AIDD patients had lower disability and fewer corpus callosum and posterior fossa lesions than MS and NMOSD. Three clusters emerged: (1) myelitis‐predominant with unmatched CSF oligoclonal bands and longitudinally extensive spinal lesions, (2) brainstem‐dominant with recurrent brainstem attacks, and (3) optic neuritis‐dominant with recurrent LEON meeting MS dissemination criteria. Treatment patterns differed; rituximab was most frequent. Conclusion: Double‐seronegative AIDD represents a heterogeneous clinical spectrum. Unsupervised clustering provides a data‐driven framework for refining phenotypic classification and may support biomarker and therapeutic development in antibody‐negative CNS demyelination.
- 9 April 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (11) , 2206-2216
Open AccessUnderstanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering
Background: Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap. Some patients remain double‐seronegative, showing atypical features that challenge current classifications. Objective: To better characterize the phenotypic spectrum of antibody‐negative atypical inflammatory demyelinating disorders (AIDD) using unsupervised clustering. Methods: We retrospectively analyzed 316 patients (MS = 164, AQP4 + NMOSD = 36, double‐seronegative NMOSD = 21, MOGAD = 15, AIDD = 80) followed between 2010 and 2023. Principal component analysis and k‐means clustering were applied to AIDD cases using clinical, demographic, and radiological data. Results: AIDD patients had lower disability and fewer corpus callosum and posterior fossa lesions than MS and NMOSD. Three clusters emerged: (1) myelitis‐predominant with unmatched CSF oligoclonal bands and longitudinally extensive spinal lesions, (2) brainstem‐dominant with recurrent brainstem attacks, and (3) optic neuritis‐dominant with recurrent LEON meeting MS dissemination criteria. Treatment patterns differed; rituximab was most frequent. Conclusion: Double‐seronegative AIDD represents a heterogeneous clinical spectrum. Unsupervised clustering provides a data‐driven framework for refining phenotypic classification and may support biomarker and therapeutic development in antibody‐negative CNS demyelination.
- Open Access
- 8 January 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (1) , 67
Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder
Objective: To evaluate the real-world effectiveness and safety of eculizumab in patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder (NMOSD) and to identify predictors of disability outcomes. Methods: This multinational, retrospective cohort study analyzed data from 46 patients across 26 centers. The outcomes included the annualized relapse rate (ARR), relapse-free status, change in expanded disability status scale (EDSS) scores, and adverse events. To identify predictors of EDSS improvement or worsening, patients were stratified into subgroups (improved vs. stable/worsened) at each follow-up time point and compared based on demographic, clinical, and radiological variables. Results: This retrospective cohort study included 46 patients with AQP4-IgG-positive NMOSD from 26 centers, followed for a mean of 27.3 months. The mean ARR significantly decreased from 1.1 in the 2 years pre-treatment to 0.1 during eculizumab therapy. The relapse-free rate increased from 6.5% pre-treatment to 80.4%. Mean EDSS scores improved from 4.2 at baseline to 3.6 at 24 months. The presence of area postrema syndrome was associated with a favorable prognosis, while the presence of spinal attacks was associated with a poor prognosis at 12 months. Adverse events occurred in 7 patients (18.9%), leading to permanent discontinuation in only two. Conclusion: Eculizumab demonstrated robust real-world effectiveness in reducing relapse rates and stabilizing disability, with an acceptable safety profile. Clinical outcomes may be influenced by attack phenotype, underscoring the importance of early intervention.
- 8 January 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (1) , 67
Open AccessReal-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder
Objective: To evaluate the real-world effectiveness and safety of eculizumab in patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder (NMOSD) and to identify predictors of disability outcomes. Methods: This multinational, retrospective cohort study analyzed data from 46 patients across 26 centers. The outcomes included the annualized relapse rate (ARR), relapse-free status, change in expanded disability status scale (EDSS) scores, and adverse events. To identify predictors of EDSS improvement or worsening, patients were stratified into subgroups (improved vs. stable/worsened) at each follow-up time point and compared based on demographic, clinical, and radiological variables. Results: This retrospective cohort study included 46 patients with AQP4-IgG-positive NMOSD from 26 centers, followed for a mean of 27.3 months. The mean ARR significantly decreased from 1.1 in the 2 years pre-treatment to 0.1 during eculizumab therapy. The relapse-free rate increased from 6.5% pre-treatment to 80.4%. Mean EDSS scores improved from 4.2 at baseline to 3.6 at 24 months. The presence of area postrema syndrome was associated with a favorable prognosis, while the presence of spinal attacks was associated with a poor prognosis at 12 months. Adverse events occurred in 7 patients (18.9%), leading to permanent discontinuation in only two. Conclusion: Eculizumab demonstrated robust real-world effectiveness in reducing relapse rates and stabilizing disability, with an acceptable safety profile. Clinical outcomes may be influenced by attack phenotype, underscoring the importance of early intervention.
- 19 February 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (6) , 2737-2746
Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population
Objectives This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists. Methods Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics. Results The study included 1021 MS patients with a mean age of 35.69 ± 9.07 years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10 years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10 years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p < 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16 years. Conclusion Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.
- 19 February 2025
- Published by Springer Nature in Neurological Sciences
- Vol. 46 (6) , 2737-2746
Treatment Adherence in a Large Cohort of Turkish Multiple Sclerosis Population
Objectives This study aimed to evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) and to identify factors influencing compliance, based on perceptions and preferences of both patients and neurologists. Methods Questionnaires were designed by a team of experts, including MS specialists, psychologists, and statisticians, to capture data on treatment adherence and related factors. A total of 1021 MS patients and their neurologists participated. Patients' adherence to oral, injectable, and infusion DMTs was assessed alongside demographic and disease-related characteristics. Results The study included 1021 MS patients with a mean age of 35.69 ± 9.07 years. Infusion therapies demonstrated the highest adherence rates (96.6%). Among all patients, 78.9% maintained treatment without interruption, while 56.7% of those who interrupted therapy informed their physicians. Patients with a disease duration of less than one year or more than 10 years exhibited lower rates of treatment interruption compared to those with a disease duration of 1–10 years (p = 0.032). In the injectable DMT group, significant differences in adherence were noted (p < 0.001). The lowest interruption rate (13.5%) was seen in patients with a disease duration of less than one year, whereas interruption rates were markedly higher (83%) in those with a duration exceeding 16 years. Conclusion Improving adherence requires a patient-centered, collaborative approach emphasizing shared decision-making between physicians and patients. Addressing factors that contribute to non-compliance is essential for optimizing treatment outcomes and enhancing long-term disease management in MS.
- Open Access
- 18 February 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (1) , 127-139
Evaluation of nonmotor symptoms in myasthenia gravis patients
Background/aim: Myasthenia gravis (MG) is chronic autoimmune disorder characterized primarily by muscle weakness and fatigue, due to autoantibodies targeting acetylcholine receptor at neuromuscular junction. In this study, we aimed to evaluate non-motor symptoms in myasthenia gravis patients and compare them with disease duration, severity and clinical features.Materials and methods: This prospective study was conducted with thirty-five myasthenia gravis patients and thirty-five healthy volunteers. Total of 35 patients, 17 women and 18 men with mean age of 52.9±13.6 years constituted patient group. Control group consisted of total of 35 participants, 23 women and 12 men with mean age of 46.9±12.2 years. Patient group was applied scales of MG Foundation of America clinical classification, MG Composite and Turkish version of MG Quality of Life 15. For non-motor functions, both in patients and controls; we used the inquiry questionnaires evaluating symptoms of headache, pain, depression, anxiety, sleep, physical activity, cognition, smell and taste. Results: Results revealed prevalent and diverse non-motor symptoms in MG patients. Montreal Cognitive Assessment (MoCA) score and degree of olfactory function in cinnamon in patient group was significantly (p<0.05) lower than control group. Rate of impaired MoCA degree, headache rate, Beck depression score, depression rate, Beck anxiety score, anxiety rate, Pittsburgh Sleep Quality Index (PSQI) score, rate of poor PSQI in patient group was significantly (p<0.05) higher than control group.Conclusion: In conclusion, our study emphasizes importance of recognizing and managing non-motor symptoms in MG patients, advocating for multidisciplinary approach to care that addresses both motor and non-motor manifestations. By expanding our understanding of MG's systemic impact and exploring new treatment modalities, we can improve lives of those living with this complex autoimmune disorder. Further research is needed to elucidate pathogenic mechanisms underlying these non-motor manifestations, which will be pivotal in developing more targeted and effective therapeutic strategies.
- 18 February 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (1) , 127-139
Open AccessEvaluation of nonmotor symptoms in myasthenia gravis patients
Background/aim: Myasthenia gravis (MG) is chronic autoimmune disorder characterized primarily by muscle weakness and fatigue, due to autoantibodies targeting acetylcholine receptor at neuromuscular junction. In this study, we aimed to evaluate non-motor symptoms in myasthenia gravis patients and compare them with disease duration, severity and clinical features.Materials and methods: This prospective study was conducted with thirty-five myasthenia gravis patients and thirty-five healthy volunteers. Total of 35 patients, 17 women and 18 men with mean age of 52.9±13.6 years constituted patient group. Control group consisted of total of 35 participants, 23 women and 12 men with mean age of 46.9±12.2 years. Patient group was applied scales of MG Foundation of America clinical classification, MG Composite and Turkish version of MG Quality of Life 15. For non-motor functions, both in patients and controls; we used the inquiry questionnaires evaluating symptoms of headache, pain, depression, anxiety, sleep, physical activity, cognition, smell and taste. Results: Results revealed prevalent and diverse non-motor symptoms in MG patients. Montreal Cognitive Assessment (MoCA) score and degree of olfactory function in cinnamon in patient group was significantly (p<0.05) lower than control group. Rate of impaired MoCA degree, headache rate, Beck depression score, depression rate, Beck anxiety score, anxiety rate, Pittsburgh Sleep Quality Index (PSQI) score, rate of poor PSQI in patient group was significantly (p<0.05) higher than control group.Conclusion: In conclusion, our study emphasizes importance of recognizing and managing non-motor symptoms in MG patients, advocating for multidisciplinary approach to care that addresses both motor and non-motor manifestations. By expanding our understanding of MG's systemic impact and exploring new treatment modalities, we can improve lives of those living with this complex autoimmune disorder. Further research is needed to elucidate pathogenic mechanisms underlying these non-motor manifestations, which will be pivotal in developing more targeted and effective therapeutic strategies.
- 4 April 2024
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- Vol. 33 (1) , 125-135
Microstructural analysis of verbal fluency performance in relapsing-remitting multiple sclerosis based on the impact of disability level
Verbal fluency (VF) evaluates language and cognitive abilities. This study compared VF in Relapsing-Remitting Multiple Sclerosis (RRMS) and healthy controls (HC), examining variables including correct responses (CR), mean cluster size (MCS), switches (S), and fluency difference score (FDS). RRMS participants were subgrouped by Expanded Disability Status Scale (EDSS), to explore the relationship between MS severity and VF. Twenty-four RRMS participants and matched HCs underwent Mini-Mental State Exam and VF Test. Statistical analysis compared VF between RRMS subgroups based on severity levels, and in HC. RRMS significantly impacted the CR, and S (CRSF p = 0.01, SSF p = 0.002; CRPF=0.002, SPF p = 0.002), while there was no significant difference in FDS between RRMS groups (p = 0.9). No significant relationship was found between EDSS scores, and VF subtests (CRSF p = 0.061, MCSSF p = 0.46, SSF p = 0.051, CRPF p = 0.521, MCSPF p = 0.966, SPF p = 0.599). In RRMS, our results demonstrate impairments in all VF parameters except the MCSSF+PF, and FDS. This study suggests that intact MCSSF+PF may reflect preserved verbal memory and word recall, while significant switching differences may indicate impaired cognitive flexibility. Similar FDS to those of HC suggest that no performance discrepancy in subtests in RRMS. Intact MCS might be a distinctive pattern in the early clinical stage of MS.
- 4 April 2024
- Published by Taylor & Francis in Applied Neuropsychology: Adult
- Vol. 33 (1) , 125-135
Microstructural analysis of verbal fluency performance in relapsing-remitting multiple sclerosis based on the impact of disability level
Verbal fluency (VF) evaluates language and cognitive abilities. This study compared VF in Relapsing-Remitting Multiple Sclerosis (RRMS) and healthy controls (HC), examining variables including correct responses (CR), mean cluster size (MCS), switches (S), and fluency difference score (FDS). RRMS participants were subgrouped by Expanded Disability Status Scale (EDSS), to explore the relationship between MS severity and VF. Twenty-four RRMS participants and matched HCs underwent Mini-Mental State Exam and VF Test. Statistical analysis compared VF between RRMS subgroups based on severity levels, and in HC. RRMS significantly impacted the CR, and S (CRSF p = 0.01, SSF p = 0.002; CRPF=0.002, SPF p = 0.002), while there was no significant difference in FDS between RRMS groups (p = 0.9). No significant relationship was found between EDSS scores, and VF subtests (CRSF p = 0.061, MCSSF p = 0.46, SSF p = 0.051, CRPF p = 0.521, MCSPF p = 0.966, SPF p = 0.599). In RRMS, our results demonstrate impairments in all VF parameters except the MCSSF+PF, and FDS. This study suggests that intact MCSSF+PF may reflect preserved verbal memory and word recall, while significant switching differences may indicate impaired cognitive flexibility. Similar FDS to those of HC suggest that no performance discrepancy in subtests in RRMS. Intact MCS might be a distinctive pattern in the early clinical stage of MS.
- 10 May 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 75, 104761
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
- 10 May 2023
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 75, 104761
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
- 27 January 2023
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 43, 1-5
Ocrelizumab in pediatric multiple sclerosis
- 27 January 2023
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 43, 1-5
Ocrelizumab in pediatric multiple sclerosis
- 12 April 2022
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 217, 107244
Prevalence of clinical manifestations and neuroimaging features in cerebral small vessel disease
- 12 April 2022
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 217, 107244
Prevalence of clinical manifestations and neuroimaging features in cerebral small vessel disease
- Open Access
Investigation of multiple sclerosis-related pathways through the integration of genomic and proteomic data
Background: Multiple sclerosis (MS) has a complex pathophysiology, variable clinical presentation, and unpredictable prognosis; understanding the underlying mechanisms requires combinatorial approaches that warrant the integration of diverse molecular omics data. Methods: Here, we combined genomic and proteomic data of the same individuals among a Turkish MS patient group to search for biologically important networks. We previously identified differentially-expressed proteins by cerebrospinal fluid proteome analysis of 179 MS patients and 42 non-MS controls. Among this study group, 11 unrelated MS patients and 60 independent, healthy controls were subjected to whole-genome SNP genotyping, and genome-wide associations were assessed. Pathway enrichment analyses of MS-associated SNPs and differentially-expressed proteins were conducted using the functional enrichment tool, PANOGA. Results: Nine shared pathways were detected between the genomic and proteomic datasets after merging and clustering the enriched pathways. Complement and coagulation cascade was the most significantly associated pathway (hsa04610, P = 6.96 × 10−30). Other pathways involved in neurological or immunological mechanisms included adherens junctions (hsa04520, P = 6.64 × 10−25), pathogenic Escherichia coli infection (hsa05130, P = 9.03 × 10−14), prion diseases (hsa05020, P = 5.13 × 10−13). Conclusion: We conclude that integrating multiple datasets of the same patients helps reducing false negative and positive results of genome-wide SNP associations and highlights the most prominent cellular players among the complex pathophysiological mechanisms.
Open AccessInvestigation of multiple sclerosis-related pathways through the integration of genomic and proteomic data
Background: Multiple sclerosis (MS) has a complex pathophysiology, variable clinical presentation, and unpredictable prognosis; understanding the underlying mechanisms requires combinatorial approaches that warrant the integration of diverse molecular omics data. Methods: Here, we combined genomic and proteomic data of the same individuals among a Turkish MS patient group to search for biologically important networks. We previously identified differentially-expressed proteins by cerebrospinal fluid proteome analysis of 179 MS patients and 42 non-MS controls. Among this study group, 11 unrelated MS patients and 60 independent, healthy controls were subjected to whole-genome SNP genotyping, and genome-wide associations were assessed. Pathway enrichment analyses of MS-associated SNPs and differentially-expressed proteins were conducted using the functional enrichment tool, PANOGA. Results: Nine shared pathways were detected between the genomic and proteomic datasets after merging and clustering the enriched pathways. Complement and coagulation cascade was the most significantly associated pathway (hsa04610, P = 6.96 × 10−30). Other pathways involved in neurological or immunological mechanisms included adherens junctions (hsa04520, P = 6.64 × 10−25), pathogenic Escherichia coli infection (hsa05130, P = 9.03 × 10−14), prion diseases (hsa05020, P = 5.13 × 10−13). Conclusion: We conclude that integrating multiple datasets of the same patients helps reducing false negative and positive results of genome-wide SNP associations and highlights the most prominent cellular players among the complex pathophysiological mechanisms.